Metformin (Active Rescue) — Competitive Intelligence Brief

Metformin (Active Rescue) (Metformin (Active Rescue)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMPK (AMP-activated protein kinase) Diabetes Small molecule

Target snapshot

Metformin (Active Rescue) (Metformin (Active Rescue)) — AstraZeneca. Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin (Active Rescue) TARGET	Metformin (Active Rescue)	AstraZeneca	phase 3	Biguanide	AMPK (AMP-activated protein kinase)
Metformin / Placebo treatment for 4 months	Metformin / Placebo treatment for 4 months	Norwegian University of Science and Technology	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
GLIMEPIRIDE + METFORMIN	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
or Metformin HCl alone	or Metformin HCl alone	Bristol-Myers Squibb	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Mandated back ground therapy	Mandated back ground therapy	Sanofi	marketed	biguanide
Placebo plus metformin	Placebo plus metformin	University Magna Graecia	marketed	Biguanide	AMP-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class